NASDAQ:CNTB Connect Biopharma - CNTB Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. $1.28 +0.05 (+4.05%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.23▼$1.3150-Day Range$0.70▼$1.2952-Week Range$0.56▼$5.10Volume83,725 shsAverage Volume55,618 shsMarket Capitalization$70.78 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Connect Biopharma MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside1,612.1% Upside$22.00 Price TargetShort InterestHealthy0.22% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.76) to ($2.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.33 out of 5 starsMedical Sector293rd out of 1,053 stocksPharmaceutical Preparations Industry133rd out of 519 stocks 3.3 Analyst's Opinion Consensus RatingConnect Biopharma has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.00, Connect Biopharma has a forecasted upside of 1,612.1% from its current price of $1.29.Amount of Analyst CoverageConnect Biopharma has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.22% of the float of Connect Biopharma has been sold short.Short Interest Ratio / Days to CoverConnect Biopharma has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Connect Biopharma has recently decreased by 12.46%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldConnect Biopharma does not currently pay a dividend.Dividend GrowthConnect Biopharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CNTB. Previous Next 3.1 News and Social Media Coverage News SentimentConnect Biopharma has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Connect Biopharma this week, compared to 0 articles on an average week.MarketBeat FollowsOnly 1 people have added Connect Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Connect Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders22.60% of the stock of Connect Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 23.14% of the stock of Connect Biopharma is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Connect Biopharma are expected to decrease in the coming year, from ($1.76) to ($2.12) per share.Price to Book Value per Share RatioConnect Biopharma has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Connect Biopharma (NASDAQ:CNTB) StockConnect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.Read More Receive CNTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTB Stock News HeadlinesJanuary 29, 2023 | seekingalpha.comConnect Biopharma: A Last Hurrah From CBP-307December 30, 2022 | seekingalpha.comConnect Biopharma delays pivotal study for lead candidateFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.December 30, 2022 | finance.yahoo.comConnect Biopharma Provides Business and Clinical Development Program UpdateDecember 19, 2022 | finance.yahoo.comConnect Biopharma to Present at the San Francisco Biotech Showcase in JanuaryOctober 27, 2022 | finance.yahoo.comConnect Biopharma To Present at Upcoming Investor and Scientific ConferencesOctober 20, 2022 | reuters.comConnect Biopharma Holdings LtdOctober 6, 2022 | benzinga.comThinking about buying stock in Connect Biopharma, Rivian Automotive, AeroClean Technologies, Kiora Pharmaceuticals, or Humanigen?February 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.October 4, 2022 | finance.yahoo.comConnect Biopharma Lead Candidate Aces Pivotal Atopic Dermatitis Trial In Chinese PatientsOctober 4, 2022 | seekingalpha.comConnect stock dips despite eczema drug CBP-201 meeting main goal in China trialOctober 4, 2022 | finance.yahoo.comConnect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in ChinaOctober 4, 2022 | finance.yahoo.comCORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in ChinaOctober 3, 2022 | finance.yahoo.comConnect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic DermatitisSeptember 26, 2022 | seekingalpha.comConnect Biopharma Is A Sleeper Heading Into October Data ReadoutSeptember 14, 2022 | finance.yahoo.comEdited Transcript of CNTB.OQ earnings conference call or presentation 13-Sep-22 8:30pm GMTSeptember 13, 2022 | it.tmcnet.comConnect Biopharma Reports First Half 2022 Financial Results and Provides Business UpdateSeptember 13, 2022 | finance.yahoo.comConnect Biopharma Reports First Half 2022 Financial Results and Provides Business UpdateAugust 30, 2022 | msn.comConnect Biopharma's Candidate For Skin Disease-Associated Itch Shows Encouraging Safety ProfileAugust 30, 2022 | finance.yahoo.comConnect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose StudyJuly 28, 2022 | wsj.comConnect Biopharma Holdings Ltd. ADRJuly 12, 2022 | finance.yahoo.comConnect Biopharma Sees CBP-201 Topline Data From China Atopic Dermatitis Trial This YearJune 17, 2022 | finance.yahoo.comConnect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementJune 8, 2022 | finance.yahoo.comAll You Need to Know About Connect Biopharma Holdings Limited Sponsored ADR (CNTB) Rating Upgrade to BuyJune 2, 2022 | finance.yahoo.comConnect Biopharma to Participate at the Jefferies Healthcare ConferenceMay 17, 2022 | finance.yahoo.comConnect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data at the Society for Investigative Dermatology Annual ConferenceMay 4, 2022 | finance.yahoo.comConnect Biopharma Stock Plunges As Ulcerative Colitis Candidate Flunks In Mid-Stage StudySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CNTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Connect Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTB Company Calendar Today2/02/2023Next Earnings (Estimated)3/30/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CNTB CUSIPN/A CIK1835268 Webwww.connectbiopharm.com Phone86-512-5357-7866FaxN/AEmployees62Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.00 High Stock Price Forecast$22.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+1,612.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio9.58 Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.73 per share Price / Book0.27Miscellaneous Outstanding Shares55,080,000Free Float42,629,000Market Cap$70.78 million OptionableNot Optionable Beta-0.44 Key ExecutivesDr. Wubin Pan M.B.A. (Age 57)Ph.D., Co-Founder, Pres & Chairman of Directors Dr. Zheng Wei Ph.D. (Age 58)Co-Founder, CEO & Director Mr. Steven Chan (Age 50)Chief Financial Officer Mr. Jiang Bian J.D.Gen. Counsel & Chief Compliance OfficerDr. Lei Sun Ph.D. (Age 58)VP of Biologics & Head of CMC Dr. Raul Collazo Ph.D.VP & Global Head of Medical AffairsDr. Malinda V. Longphre Ph.D.Head of US Clinical OperationsDr. Chin Lee M.D. (Age 52)M.P.H., Chief Medical Officer More ExecutivesKey CompetitorsSpruce BiosciencesNASDAQ:SPRBTiziana Life SciencesNASDAQ:TLSAGalectin TherapeuticsNASDAQ:GALTTonix PharmaceuticalsNASDAQ:TNXPOncternal TherapeuticsNASDAQ:ONCTView All CompetitorsInsiders & InstitutionsRenaissance Technologies LLCBought 16,400 shares on 11/14/2022Ownership: 0.151%Boothbay Fund Management LLCSold 50,984 shares on 11/14/2022Ownership: 0.049%View All Institutional Transactions CNTB Stock - Frequently Asked Questions Should I buy or sell Connect Biopharma stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Connect Biopharma in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNTB shares. View CNTB analyst ratings or view top-rated stocks. What is Connect Biopharma's stock price forecast for 2023? 3 Wall Street research analysts have issued 1-year price targets for Connect Biopharma's shares. Their CNTB share price forecasts range from $22.00 to $22.00. On average, they anticipate the company's stock price to reach $22.00 in the next year. This suggests a possible upside of 1,612.1% from the stock's current price. View analysts price targets for CNTB or view top-rated stocks among Wall Street analysts. How have CNTB shares performed in 2023? Connect Biopharma's stock was trading at $0.8678 at the beginning of 2023. Since then, CNTB stock has increased by 48.1% and is now trading at $1.2850. View the best growth stocks for 2023 here. When is Connect Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023. View our CNTB earnings forecast. When did Connect Biopharma IPO? (CNTB) raised $150 million in an initial public offering (IPO) on Friday, March 19th 2021. The company issued 9,400,000 shares at $15.00-$17.00 per share. Jefferies, VB Leerink, Piper Sandler and CICC served as the underwriters for the IPO. What is Connect Biopharma's stock symbol? Connect Biopharma trades on the NASDAQ under the ticker symbol "CNTB." Who are Connect Biopharma's major shareholders? Connect Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Connect Biopharma? Shares of CNTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Connect Biopharma's stock price today? One share of CNTB stock can currently be purchased for approximately $1.29. How much money does Connect Biopharma make? Connect Biopharma (NASDAQ:CNTB) has a market capitalization of $70.77 million. How can I contact Connect Biopharma? Connect Biopharma's mailing address is East R&D Building 3rd Floor Science and Technology Park 6 Beijing West Road, TAICANG F4, 215400. The official website for the company is www.connectbiopharm.com. The company can be reached via phone at 86-512-5357-7866 or via email at david.carey@finnpartners.com. This page (NASDAQ:CNTB) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.